<h2>关键点</h2>
<ul>
<li>Arcalyst 已在市场上销售多年，但在此期间销售增长强劲。</li>
<li>显然，更多的增长即将到来，因为管理层提高了该药物的净销售指引。</li>
<li>我们更看好的 10 只股票超过 Kiniksa Pharmaceuticals International ›</li>
</ul>
<p><strong>Kiniksa Pharmaceuticals International</strong>（NASDAQ: KNSA）在周二的国内股票交易中表现相当出色。它发布了首份 2026 年财报，关键基本面超出分析师预期，感激的投资者纷纷涌入该股，推动其当天上涨近 24%。</p>
<h2>长期成功</h2>
<p>Kiniksa 是一家商业阶段的生物技术公司，专注于满足重大未满足需求的疾病，周二上午发布了第一季度数据。这显示其收入完全来自多适应症药物 Arcalyst 的销售，收入从去年不足 1.38 亿美元上升至超过 2.14 亿美元。</p>
<p><em><strong>人工智能会创造出世界上第一个万亿富翁吗？</strong> 我们的团队刚刚发布了一份关于一家鲜为人知的公司报告，该公司被称为 “不可或缺的垄断”，提供 Nvidia 和 Intel 都需要的关键技术。<strong>继续 »</strong></em></p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2NzU5Ny9wZXJzb24tY2hlY2tpbmctbWVkaWNpbmUtb24tYS1zaGVsZi1pbi1hLXBoYXJtYWN5LmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="700" height="467" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2NzU5Ny9wZXJzb24tY2hlY2tpbmctbWVkaWNpbmUtb24tYS1zaGVsZi1pbi1hLXBoYXJtYWN5LmpwZyZ3PTcwMA"/></p>
<p>图片来源：Getty Images。</p>
<p>根据公认会计原则（GAAP），净收入则从 2025 年第一季度的 850 万美元（每股 0.27 美元）翻倍至 2260 万美元。</p>
<p>这两个头条数据都明显超出分析师的共识预期。跟踪 Kiniksa 股票的专家们普遍预测收入略超过 2.07 亿美元，GAAP 每股盈利为 0.21 美元。</p>
<p>Kiniksa 指出，Arcalyst 最近获得的心脏疾病心包炎的批准是其近期受欢迎的驱动因素。这激励管理层将该药物今年的净销售预测提高至 9.3 亿至 9.45 亿美元。之前的预测为 9 亿至 9.2 亿美元。</p>
<h2>积极迹象</h2>
<p>虽然我对只有一种产品在药房销售的商业阶段生物技术公司持谨慎态度，但多年来，Arcalyst 已证明其相当多才多艺。我预计它也会获得其他适应症的批准，因为 Kiniksa 还在研究其他疾病。因此，最终我对 Kiniksa 的前景持乐观态度。</p>
<h2>你现在应该购买 Kiniksa Pharmaceuticals International 的股票吗？</h2>
<p>在你购买 Kiniksa Pharmaceuticals International 的股票之前，请考虑以下几点：</p>
<p><em>Motley Fool Stock Advisor</em> 分析师团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong>，供投资者现在购买……而 Kiniksa Pharmaceuticals International 并不在其中。这 10 只入选的股票在未来几年可能会产生巨额回报。</p>
<p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日进入这个名单时……如果你在我们推荐时投资了 1000 美元，<strong>你现在将拥有 492,752 美元</strong>！* 或者 <strong>Nvidia</strong> 在 2005 年 4 月 15 日进入这个名单时……如果你在我们推荐时投资了 1000 美元，<strong>你现在将拥有 1,327,935 美元</strong>！*</p>
<p>现在值得注意的是，<em>Stock Advisor</em> 的总平均回报率为 991%——相比之下，标准普尔 500 指数的回报率为 201%，表现优异。<strong>不要错过最新的前 10 名单，加入由个人投资者为个人投资者建立的投资社区，获取 <em>Stock Advisor</em> 的最新信息。</strong></p>
<p><strong>查看这 10 只股票 »</strong></p>
<p><em>*Stock Advisor 的回报截至 2026 年 4 月 28 日。</em></p>
<p><em>Eric Volkman 在提到的任何股票中没有持仓。Motley Fool 在 Kiniksa Pharmaceuticals International, Plc 中持有头寸并推荐该股票。Motley Fool 有披露政策。</em></p>
<p>此处表达的观点和意见是作者的观点和意见，并不一定反映 Nasdaq, Inc. 的观点。</p>

KNSA

<p>Kiniksa Pharmaceuticals International（纳斯达克股票代码：KNSA）在发布其首份 2026 年财报后，股价飙升近 24%，超出分析师预期。该公司来自其药物 Arcalyst 的收入超过 2.14 亿美元，较去年不足 1.38 亿美元的收入大幅增长，而净收入则翻倍至 2260 万美元。管理层将 Arcalyst 的净销售指导上调至 9.3 亿至 9.45 亿美元，指出最近获得的心包炎治疗批准是其成功的关键因素。尽管如此，分析师建议考虑其他股票进行投资</p>

<h2>Key Points</h2>
<div class="lb-trans"><h2>关键点</h2>
</div><ul>
<li>Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period.</li>
<li>More is to come, apparently, as management raised its net sales guidance for the drug.</li>
<li>10 stocks we like better than Kiniksa Pharmaceuticals International ›</li>
</ul>
<div class="lb-trans"><ul>
<li>Arcalyst 已在市场上销售多年，但在此期间销售增长强劲。</li>
<li>显然，更多的增长即将到来，因为管理层提高了该药物的净销售指引。</li>
<li>我们更看好的 10 只股票超过 Kiniksa Pharmaceuticals International ›</li>
</ul>
</div><p><strong>Kiniksa Pharmaceuticals International</strong>(NASDAQ: KNSA) was quite a hit on our domestic stock exchange in Tuesday's trading session. It released its inaugural 2026 earnings report and, with key fundamentals that beat analyst estimates, grateful investors rushed into the stock, lifting it by almost 24% that day.</p>
<div class="lb-trans"><p><strong>Kiniksa Pharmaceuticals International</strong>（NASDAQ: KNSA）在周二的国内股票交易中表现相当出色。它发布了首份 2026 年财报，关键基本面超出分析师预期，感激的投资者纷纷涌入该股，推动其当天上涨近 24%。</p>
</div><h2>Long-tail success</h2>
<div class="lb-trans"><h2>长期成功</h2>
</div><p>Kiniksa, a commercial-stage biotech targeting afflictions with significant unmet need, published its first-quarter figures Tuesday morning. This revealed that revenue, comprised entirely of sales of multi-indication drug Arcalyst, rose to over $214 million from the year-ago tally of under $138 million.</p>
<div class="lb-trans"><p>Kiniksa 是一家商业阶段的生物技术公司，专注于满足重大未满足需求的疾病，周二上午发布了第一季度数据。这显示其收入完全来自多适应症药物 Arcalyst 的销售，收入从去年不足 1.38 亿美元上升至超过 2.14 亿美元。</p>
</div><p><em><strong>Will AI create the world's first trillionaire?</strong> Our team just released a report on the one little-known company, called an &#34;Indispensable Monopoly&#34; providing the critical technology Nvidia and Intel both need. <strong>Continue »</strong></em></p>
<div class="lb-trans"><p><em><strong>人工智能会创造出世界上第一个万亿富翁吗？</strong> 我们的团队刚刚发布了一份关于一家鲜为人知的公司报告，该公司被称为 “不可或缺的垄断”，提供 Nvidia 和 Intel 都需要的关键技术。<strong>继续 »</strong></em></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2NzU5Ny9wZXJzb24tY2hlY2tpbmctbWVkaWNpbmUtb24tYS1zaGVsZi1pbi1hLXBoYXJtYWN5LmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F867597%2Fperson-checking-medicine-on-a-shelf-in-a-pharmacy.jpg&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><p>Net income under generally accepted accounting principles (GAAP), meanwhile, more than doubled to $22.6 million from first quarter 2025's $8.5 million ($0.27 per share).</p>
<div class="lb-trans"><p>根据公认会计原则（GAAP），净收入则从 2025 年第一季度的 850 万美元（每股 0.27 美元）翻倍至 2260 万美元。</p>
</div><p>Both headline figures convincingly beat the consensus analyst estimates. Pundits tracking Kiniksa stock were collectively modeling slightly over $207 million for revenue and $0.21 per share for GAAP bottom-line profitability.</p>
<div class="lb-trans"><p>这两个头条数据都明显超出分析师的共识预期。跟踪 Kiniksa 股票的专家们普遍预测收入略超过 2.07 亿美元，GAAP 每股盈利为 0.21 美元。</p>
</div><p>Kiniksa pointed to Arcalyst's success with its most recent approval, specifically for heart disorder pericarditis, as the driver of its recent popularity. This inspired management to raise its forecast for the drug's net sales this year to $930 million to $945 million. Previously, it had forecast $900 million to $920 million.</p>
<div class="lb-trans"><p>Kiniksa 指出，Arcalyst 最近获得的心脏疾病心包炎的批准是其近期受欢迎的驱动因素。这激励管理层将该药物今年的净销售预测提高至 9.3 亿至 9.45 亿美元。之前的预测为 9 亿至 9.2 亿美元。</p>
</div><h2>Positive indications</h2>
<div class="lb-trans"><h2>积极迹象</h2>
</div><p>While I tend to be wary of commercial-stage biotechs with only one product on pharmacy shelves, over the years, Arcalyst has proven to be quite versatile. I'd expect it to collect approvals for other indications, too, as it is also being investigated by Kiniksa for other afflictions. So in the end, I'd be bullish on Kiniksa's prospects.</p>
<div class="lb-trans"><p>虽然我对只有一种产品在药房销售的商业阶段生物技术公司持谨慎态度，但多年来，Arcalyst 已证明其相当多才多艺。我预计它也会获得其他适应症的批准，因为 Kiniksa 还在研究其他疾病。因此，最终我对 Kiniksa 的前景持乐观态度。</p>
</div><h2>Should you buy stock in Kiniksa Pharmaceuticals International right now?</h2>
<div class="lb-trans"><h2>你现在应该购买 Kiniksa Pharmaceuticals International 的股票吗？</h2>
</div><p>Before you buy stock in Kiniksa Pharmaceuticals International, consider this:</p>
<div class="lb-trans"><p>在你购买 Kiniksa Pharmaceuticals International 的股票之前，请考虑以下几点：</p>
</div><p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and Kiniksa Pharmaceuticals International wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<div class="lb-trans"><p><em>Motley Fool Stock Advisor</em> 分析师团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong>，供投资者现在购买……而 Kiniksa Pharmaceuticals International 并不在其中。这 10 只入选的股票在未来几年可能会产生巨额回报。</p>
</div><p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $492,752</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,327,935</strong>!*</p>
<div class="lb-trans"><p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日进入这个名单时……如果你在我们推荐时投资了 1000 美元，<strong>你现在将拥有 492,752 美元</strong>！* 或者 <strong>Nvidia</strong> 在 2005 年 4 月 15 日进入这个名单时……如果你在我们推荐时投资了 1000 美元，<strong>你现在将拥有 1,327,935 美元</strong>！*</p>
</div><p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 991% — a market-crushing outperformance compared to 201% for the S&amp;P 500. <strong>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</strong></p>
<div class="lb-trans"><p>现在值得注意的是，<em>Stock Advisor</em> 的总平均回报率为 991%——相比之下，标准普尔 500 指数的回报率为 201%，表现优异。<strong>不要错过最新的前 10 名单，加入由个人投资者为个人投资者建立的投资社区，获取 <em>Stock Advisor</em> 的最新信息。</strong></p>
</div><p><strong>See the 10 stocks »</strong></p>
<div class="lb-trans"><p><strong>查看这 10 只股票 »</strong></p>
</div><p><em>*Stock Advisor returns as of April 28, 2026.</em></p>
<div class="lb-trans"><p><em>*Stock Advisor 的回报截至 2026 年 4 月 28 日。</em></p>
</div><p><em>Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kiniksa Pharmaceuticals International, Plc. The Motley Fool has a disclosure policy.</em></p>
<div class="lb-trans"><p><em>Eric Volkman 在提到的任何股票中没有持仓。Motley Fool 在 Kiniksa Pharmaceuticals International, Plc 中持有头寸并推荐该股票。Motley Fool 有披露政策。</em></p>
</div><p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
<div class="lb-trans"><p>此处表达的观点和意见是作者的观点和意见，并不一定反映 Nasdaq, Inc. 的观点。</p>
</div>

为什么 Kiniksa Pharmaceuticals International 的股票今天飙升了近 24%